Acumen Pharmaceuticals Inc.

06/03/2026 | Press release | Distributed by Public on 06/03/2026 14:43

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 3, 2026, Acumen Pharmaceuticals, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). The stockholders considered three proposals at the Annual Meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2026. Of the 72,227,580 shares outstanding as of the record date, 57,051,456 shares, or approximately 78.99%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.
Proposal No. 1: The stockholders elected three nominees to serve as Class II directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:
Name Votes For Votes Withheld Broker Non-Votes
George Golumbeski, Ph.D. 37,305,711 68,820 19,676,925
Derrell Porter, M.D. 30,926,494 6,448,037 19,676,925
Laura Stoppel, Ph.D. 30,812,559 6,561,972 19,676,925
Proposal No. 2: The stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:
Votes For
Votes Against
Abstained
Ratification of appointment of Ernst & Young LLP
56,934,900 113,074 3,482
Proposal No. 3: The stockholders approved the Company's Amended and Restated 2021 Equity Incentive Plan. The votes were cast as follows:
Votes For
Votes Against
Abstained
Broker Non-Votes
Approval of the Company's Amended and Restated 2021 Equity Incentive Plan 30,731,776 6,618,621 24,134 19,676,925
Acumen Pharmaceuticals Inc. published this content on June 03, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 03, 2026 at 20:43 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]